Leslie SW, Soon-Sutton TL, Aeddula NR. Bladder Cancer. 2024 Aug 15. In: StatPearls (Internet). Treasure Island (FL): StatPearls Publishing; 2024.

Torre LA, Bray F, Siegel RL, Ferlay J, Lortet‐Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin 2015;65:87–108. https://doi.org/10.3322/caac.21262.

Umbas R, Safriadi F, Mochtar CA, Djatisoesanto W, Hamid ARAH. Urologic cancer in Indonesia. Jpn J Clin Oncol 2015;45:708–12. https://doi.org/10.1093/jjco/hyv066.

Gontero P, Compérat E, Dominguez-Escrig JL, et al. EAU guidelines on non-muscle-invasive bladder cancer (TaT1 and CIS). European Association of Urology;2023.

Goldberg IP, Lichtbroun B, Singer EA, Ghodoussipour S. Pharmacologic therapies for non-muscle invasive bladder cancer: current and future treatments. Arch Pharmacol Ther 2022;4:13-22.

Jin X, Zhang P, Luo L, et al. Efficient intravesical therapy of bladder cancer with cationic doxorubicin nanoassemblies. Int J Nanomedicine 2016;11:4535–44. https://doi.org/10.2147/IJN.S103994.

Belger C, Abrahams C, Imamdin A, Lecour S. Doxorubicin-induced cardiotoxicity and risk factors. IJC Heart Vasculature 2024;50:101332. https://doi.org/10.1016/j.ijcha.2023.101332.

Murabito A, Hirsch E, Ghigo A. Mechanisms of anthracycline-induced cardiotoxicity: Is mitochondrial dysfunction the answer? Front Cardiovasc Med 2020;7:35. https://doi.org/10.3389/fcvm.2020.00035.

Becker MMC, Arruda GFA, Berenguer DRF, Buril RO, Cardinale D, Brandão SCS. Anthracycline cardiotoxicity: current methods of diagnosis and possible role of 18F-FDG PET/CT as a new biomarker. Cardio-Oncology 2023;9:17. https://doi.org/10.1186/s40959-023-00161-6.

Qiu S, Zhou T, Qiu B, et al. Risk factors for anthracycline-induced cardiotoxicity. Front Cardiovasc Med 2021;8:736854. doi: 10.3389/fcvm.2021.736854.

Al Balushi J, Valko SP, Nwosu M, et al. Understanding cardiomyopathy induced by doxorubicin therapy: mechanisms, diagnosis, and management strategies. J Cardiol Cardiovasc Ther 2024;19:556012. DOI: 10.19080/JOCCT.2024.19.556012.

Zamorano JL, Lancellotti P, Rodriguez Muñoz D, et al.; ESC Scientific Document Group. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J 2016;37:2768-801. doi: 10.1093/eurheartj/ehw211. Erratum in: Eur Heart J 2018;39:839. doi: 10.1093/eurheartj/ehw562 n.d.

Kim YA, Cho H, Lee N, et al. Doxorubicin‐induced heart failure in cancer patients: a cohort study based on the Korean National Health Insurance Database. Cancer Med 2018;7:6084–92. https://doi.org/10.1002/cam4.1886.

Trasca L, Popescu MR, Popescu AC, Balanescu SM. Echocardiography in the diagnosis of cardiomyopathies: current status and future directions. Rev Cardiovasc Med 2022;23:280. https://doi.org/10.31083/j.rcm2308280.

Jin X, Zhang P, Luo L, et al. Efficient intravesical therapy of bladder cancer with cationic doxorubicin nanoassemblies. Int J Nanomedicine 2016;11:4535–44. https://doi.org/10.2147/IJN.S103994.

Seo GH, Kim JH, Ku JH. Clinical practice pattern of immediate intravesical chemotherapy following transurethral resection of a bladder tumor in Korea: National Health Insurance Database Study. Sci Rep 2016;6:22716. https://doi.org/10.1038/srep22716.

Alrabadi A, Abuhamad M, Mansi H, et al. Delayed bladder perforation related to immediate single dose intravesical doxorubicin instillation after TURBT: a case report and literature review. Clin Med Insights Case Rep 2021;14:1179547620986158. https://doi.org/10.1177/1179547620986158.

Rawat PS, Jaiswal A, Khurana A, Bhatti JS, Navik U. Doxorubicin-induced cardiotoxicity: An update on the molecular mechanism and novel therapeutic strategies for effective management. Biomed Pharmacother 2021;139:111708. doi: 10.1016/j.biopha.2021.111708.

Dulf PL, Mocan M, Coadă CA, et al. Doxorubicin-induced acute cardiotoxicity is associated with increased oxidative stress, autophagy, and inflammation in a murine model. Naunyn Schmiedebergs Arch Pharmacol 2023;396:1105–15. https://doi.org/10.1007/s00210-023-02382-z.

Akbar M, Maulana A, Widagdo Arifin S, Hairul Umam M. Cardiotoxicity caused by intravesical doxorubicin (DOX) after TURBT: a case report. Lombok J Urol 2022;1:106-11.

Lam CSP, Yancy C. Universal definition and classification of heart failure: is it universal? Does it define heart failure? J Card Fail 2021;27:509-11. doi: 10.1016/j.cardfail.2021.03.003.

Mathew T, Williams L, Navaratnam G, et al. Diagnosis and assessment of dilated cardiomyopathy: a guideline protocol from the British Society of Echocardiography. Echo Res Pract 2017;4:G1–13. doi: 10.1530/ERP-16-0037.

Jia G, Hill MA, Sowers JR. Diabetic cardiomyopathy: An update of mechanisms contributing to this clinical entity. Circ Res 2018;122:624–38. https://doi.org/10.1161/CIRCRESAHA.117.311586.